Purchase this article with an account.
Fiona Kim, Jesse L Berry, Sona Shah, Rima Jubran, Jonathan W Kim; Integrated Treatment During the Intravitreal Melphalan Era: Concurrent Intravitreal Melphalan and Systemic Chemoreduction. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1647. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Intravitreal injection of melphalan (IVM) is safe and effective for treatment of seeding in retinoblastoma (Rb). Current protocols require weekly injections during examination under anesthesia (EUA). To avoid additional anesthesia exposure for these children, IVM was initiated at the EUA concurrent with the 4th cycle of systemic chemoreduction in a series of six patients with persistent seeding.
A retrospective review was completed to assess treatment response compared to all patients at our center treated with IVM and systemic chemotherapy. Overall, 6 eyes of 6 patients were included; salvage therapy included systemic chemoreduction with vincristine, etoposide and carboplatin and intravitreal injection of melphalan for persistent seeding.
IVM was initiated in all eyes at cycle 4 of their chemotherapy. Success in eradicating vitreous seeds was 100%; overall salvage rate was 67%. Anterior toxicity was observed in 2 out of 6 eyes and posterior toxicity in 4 out 6 eyes.
The concurrent chemoreduction and IVM protocol demonstrated a similar efficacy of globe salvage while sparing children additional EUAs. However, the increased rates of observed melphalan-related toxicities for concurrent therapy are concerning. Further clinical experience is necessary to define the best time to initiate intravitreal injections for vitreous seeding, as well as the optimal number and dosing schedule for IVM.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only